Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: DYNLL1

Summary for DYNLL1

Gene information	Gene symbol	DYNLL1
	Ensembl ID	ENSG00000088986
	Entrez ID	8655
	Gene name	dynein light chain LC8-type 1
	Synonyms	DLC1\|DLC8\|DNCL1\|hdlc1\|LC8\|PIN
	Gene type	protein_coding
	UniProtAcc	P63167

Top

Dataset with differentially expressed gene: DYNLL1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.364396	0.00e+00
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	0.456526	0.00e+00
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.367007	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	-0.293476	2.68e-02
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	pDCs	-0.506654	2.13e-02
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.3389	3.52e-31
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.414099	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.424815	1.92e-39
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.30099	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.476062	1.07e-12
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.483234	1.02e-29
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	1.25646	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.251311	3.80e-25
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.267103	9.51e-03
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	0.508935	7.21e-06
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.339442	1.65e-40
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.31298	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	0.288712	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.301155	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.270332	6.76e-08
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	NK cells	-0.507905	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	0.255582	2.14e-32
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	0.328639	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	0.272545	1.11e-21
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	0.255202	1.53e-40
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD4+ T cells	0.33275	1.72e-41
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	0.353097	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	0.465406	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.342792	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	NK cells	0.263125	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	0.53009	2.74e-29
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-1.32337	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.709167	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	1.40364	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	0.59344	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.370493	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	0.476111	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.452027	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.542352	9.41e-08
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	0.343661	8.16e-03
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	Malignant cells	0.352123	3.81e-08
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.487069	8.80e-21
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	0.387375	0.00e+00
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	CD8+ T cells	-0.36763	2.40e-02
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	NK cells	-0.657931	8.78e-03
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	Malignant cells	-0.617249	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.316213	4.89e-16
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.270506	2.20e-15
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.459746	1.67e-33
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	0.265227	1.79e-19
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.617448	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	0.45232	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	1.62625	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	1.60195	0.00e+00

Top

Expression of DYNLL1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to DYNLL1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating DYNLL1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
DYNLL1	hsa-miR-4478	97.6341	NM_001037494
DYNLL1	hsa-miR-3929	97.2002	NM_001037494
DYNLL1	hsa-miR-4774-5p	94.5779	NM_001037494
DYNLL1	hsa-miR-6764-3p	94.4541	NM_001037494
DYNLL1	hsa-miR-6824-3p	94.4541	NM_001037494
DYNLL1	hsa-miR-642b-5p	93.6554	NM_001037494
DYNLL1	hsa-miR-4711-5p	93.0535	NM_001037494
DYNLL1	hsa-miR-5003-5p	87.7708	NM_001037494
DYNLL1	hsa-miR-432-3p	85.9417	NM_001037494
DYNLL1	hsa-miR-6776-3p	82.491	NM_001037494
DYNLL1	hsa-miR-1910-5p	81.662	NM_001037494
DYNLL1	hsa-miR-3191-5p	81.3803	NM_001037494
DYNLL1	hsa-miR-486-5p	80.7953	NM_001037494
DYNLL1	hsa-miR-644a	80.2349	NM_001037494

Page: 1

Top

Motifs and transcription factors (TFs) regulating DYNLL1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
DYNLL1	metacluster_46.4	CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; DBP; DBP; EP300; GATAD2A; HES2 (directAnnotation). CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPE; CEBPE; CEBPE; CEBPG; CEBPG; HLF; HLF (inferredBy_Orthology).
DYNLL1	metacluster_56.4	HSF1; HSF2; HSF2; HSF4 (directAnnotation).
DYNLL1	hocomoco__HSF1_MOUSE.H11MO.1.A	HSF1 (inferredBy_Orthology).
DYNLL1	metacluster_21.5	HOXB2; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4 (directAnnotation). HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4; HSF4; HSF5; HSF5; HSF5; HSF5; HSFX1; HSFX1; HSFX1; HSFX1; HSFX2; HSFX2; HSFX2; HSFX2; HSFX3; HSFX3; HSFX3; HSFX3; HSFX4; HSFX4; HSFX4; HSFX4; HSFY1; HSFY1; HSFY1; HSFY1; HSFY2; HSFY2; HSFY2; HSFY2 (inferredBy_Orthology).
DYNLL1	taipale__MYBL2_DBD_AACCGTTAACGGNN	MYBL2 (directAnnotation).
DYNLL1	hocomoco__HXD13_HUMAN.H11MO.0.D	HOXD13 (directAnnotation).
DYNLL1	hocomoco__PO2F1_HUMAN.H11MO.0.C	POU2F1 (directAnnotation).
DYNLL1	metacluster_21.4	HSF1; HSF1; HSF2 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology).
DYNLL1	tfdimers__MD00370	YY1; ZNF384 (directAnnotation).
DYNLL1	tfdimers__MD00281	CDX2; HNF4A; HNF4G; NR2F1; NR2F2 (directAnnotation).
DYNLL1	tfdimers__MD00394	CDX2; PAX4 (directAnnotation).
DYNLL1	transfac_pro__M05930	ZNF286A (directAnnotation).
DYNLL1	metacluster_77.14	SOX7 (inferredBy_Orthology).
DYNLL1	tfdimers__MD00342	IRF1; YY1 (directAnnotation).
DYNLL1	metacluster_56.3	HSF2 (directAnnotation).
DYNLL1	metacluster_113.4	MYB; MYB; MYBL1; MYBL2 (directAnnotation). MYB; MYB; MYBL1; MYBL2 (inferredBy_Orthology).
DYNLL1	kznf__ZNF384_Schmitges2016_RCADE	ZNF384 (directAnnotation).
DYNLL1	taipale_tf_pairs__FOXO1_ELK1_RSCGGATGTTRTN_CAP	ELK1; FOXO1 (directAnnotation).
DYNLL1	taipale_tf_pairs__HOXB2_ELK1_TAATKRCCGGAAGNN_CAP_repr	ELK1; HOXB2 (directAnnotation).
DYNLL1	metacluster_144.3	ZNF704; ZNF704 (directAnnotation).
DYNLL1	cisbp__M00788	ZFY (inferredBy_Orthology).
DYNLL1	kznf__ZNF213_Schmitges2016_RCADE	ZNF213 (directAnnotation).
DYNLL1	metacluster_125.2	TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2B; TFAP2B; TFAP2B; TFAP2B; TFAP2B; TFAP2B; TFAP2B; TFAP2B; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2D; TFAP2D; TFAP2D; TFAP2E; TFAP2E; TFAP2E; TFAP2E; TFAP2E; TFAP2E; ZNF611; ZNF611 (directAnnotation). TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2A; TFAP2B; TFAP2B; TFAP2B; TFAP2B; TFAP2B; TFAP2B; TFAP2B; TFAP2B; TFAP2B; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2C; TFAP2D; TFAP2D; TFAP2D; TFAP2D; TFAP2D; TFAP2D; TFAP2E; TFAP2E; TFAP2E; TFAP2E; TFAP2E; TFAP2E; TFAP2E (inferredBy_Orthology).
DYNLL1	kznf__ZNF682_Isakova2017_SMiLE-seq	ZNF682 (directAnnotation).
DYNLL1	cisbp__M01863	ZNF711 (inferredBy_Orthology).
DYNLL1	taipale_cyt_meth__ZNF460_NRMCGCCCCCCGN_eDBD_meth	ZNF460 (directAnnotation).
DYNLL1	tfdimers__MD00157	MYB; TLX2 (directAnnotation).
DYNLL1	tfdimers__MD00416	HNF1A; HNF1B (directAnnotation).
DYNLL1	taipale_tf_pairs__ELK1_EVX1_RSCGGWANNNNYMATTA_CAP_repr	ELK1; EVX1 (directAnnotation).
DYNLL1	transfac_pro__M05836	ZNF572 (directAnnotation).
DYNLL1	metacluster_20.5	DLX1; DLX4; DLX4 (directAnnotation).
DYNLL1	taipale_tf_pairs__ETV2_HOXA2_NCCGGAAGNNNNNNYMATTA_CAP	ETV2; HOXA2 (directAnnotation).
DYNLL1	transfac_pro__M05539	OSR2 (inferredBy_Orthology).
DYNLL1	transfac_pro__M04856	BATF (directAnnotation).
DYNLL1	jaspar__MA1509.1	IRF6 (directAnnotation).
DYNLL1	metacluster_2.8	IRF4; IRF5; IRF6; IRF9 (directAnnotation). IRF3; IRF5; IRF5; IRF6 (inferredBy_Orthology).
DYNLL1	taipale_cyt_meth__IRF6_ACCGAWACY_FL_meth	IRF6 (directAnnotation).
DYNLL1	transfac_pro__M05927	ZNF408 (directAnnotation).
DYNLL1	transfac_pro__M06519	ZNF397 (directAnnotation).
DYNLL1	tfdimers__MD00415	PDX1; POU3F2 (directAnnotation).
DYNLL1	taipale_tf_pairs__ETV2_DLX3_RSCGGAANNNNNNNTAATKR_CAP_repr	DLX3; ETV2 (directAnnotation).
DYNLL1	metacluster_132.4	MEF2B; MEF2B; MEF2B; MEF2B; MEF2C; MEF2C; MEF2D; MEF2D; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF (directAnnotation). SRF; SRF; SRF; SRF (inferredBy_Orthology).
DYNLL1	taipale_tf_pairs__HOXB2_ETV1_ACCGGAAATGA_CAP	ETV1; HOXB2 (directAnnotation).
DYNLL1	transfac_pro__M01122	ZNF219 (directAnnotation).
DYNLL1	metacluster_7.5	PLAGL1; PLAGL1 (directAnnotation).
DYNLL1	dbtfbs__ZSCAN30_HEK293_ENCSR768VNZ_merged_N1	ZSCAN30 (directAnnotation).
DYNLL1	metacluster_170.2	KLF1; KLF10; KLF10; KLF11; KLF11; KLF11; KLF12; KLF12; KLF14; KLF15; KLF17; KLF2; KLF5; KLF7; KLF7; KLF8; MAZ; MAZ; PATZ1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP4; SP4; SP5; SP6; SP7; SP8; SP9; ZNF281 (directAnnotation). E2F1; E2F4; KLF10; KLF13; KLF14; KLF17; KLF2; KLF7; SP1; SP1; SP3; SP4; SP5; SP6; SP7 (inferredBy_Orthology).
DYNLL1	taipale_tf_pairs__TFAP2C_E2F8_NNTCCCGCNNNCCNNNGGC_CAP_repr	E2F8; TFAP2C (directAnnotation).
DYNLL1	transfac_pro__M01199	TRIM28 (directAnnotation).
DYNLL1	metacluster_163.1	KLF1; KLF1; KLF1; KLF1; KLF1; KLF1; KLF1; KLF10; KLF10; KLF12; KLF12; KLF12; KLF13; KLF16; KLF17; KLF2; KLF3; KLF3; KLF3; KLF3; KLF4; KLF4; KLF4; KLF4; KLF4; KLF5; KLF5; KLF5; KLF5; KLF6; KLF6; KLF6; KLF7; KLF9; KLF9; SALL4; SP1; ZNF148; ZNF148; ZNF526 (directAnnotation). EGR4; KLF1; KLF1; KLF12; KLF12; KLF12; KLF13; KLF14; KLF14; KLF14; KLF14; KLF14; KLF14; KLF16; KLF17; KLF17; KLF17; KLF17; KLF17; KLF18; KLF18; KLF18; KLF18; KLF18; KLF18; KLF2; KLF2; KLF3; KLF4; KLF4; KLF4; KLF4; KLF4; KLF4; KLF5; KLF5; KLF5; KLF6; KLF7; KLF7; KLF8; KLF8; KLF9; SP4; SP5; SP5; SP6; SP7; SP8; SP9; ZNF526 (inferredBy_Orthology).

Page: 1 2 3 4 5

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."